loading
前日終値:
$17.69
開ける:
$18.18
24時間の取引高:
623.87K
Relative Volume:
1.07
時価総額:
$1.15B
収益:
$1.23M
当期純損益:
$-214.90M
株価収益率:
-4.352
EPS:
-4.1222
ネットキャッシュフロー:
$-151.25M
1週間 パフォーマンス:
-1.27%
1か月 パフォーマンス:
-2.34%
6か月 パフォーマンス:
-37.03%
1年 パフォーマンス:
-52.70%
1日の値動き範囲:
Value
$17.39
$18.27
1週間の範囲:
Value
$16.71
$19.50
52週間の値動き範囲:
Value
$16.71
$40.84

Spyre Therapeutics Inc Stock (SYRE) Company Profile

Name
名前
Spyre Therapeutics Inc
Name
セクター
Healthcare (1166)
Name
電話
(617) 651-5940
Name
住所
221 CRESCENT STREET, WALTHAM
Name
職員
0
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
SYRE's Discussions on Twitter

SYRE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SYRE
Spyre Therapeutics Inc
17.94 1.15B 1.23M -214.90M -151.25M -4.1222
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-18 開始されました Wolfe Research Outperform
2024-09-04 開始されました Wedbush Outperform
2024-07-16 開始されました Evercore ISI Outperform
2024-05-02 開始されました Robert W. Baird Outperform
2024-03-01 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-20 開始されました BTIG Research Buy
2023-12-11 開始されました Guggenheim Buy
2023-12-11 開始されました Jefferies Buy
2020-05-04 開始されました Piper Sandler Overweight
2019-03-21 開始されました JP Morgan Overweight
2018-09-04 ダウングレード Wells Fargo Outperform → Market Perform
2018-04-24 開始されました Evercore ISI Outperform
2018-03-14 繰り返されました Needham Buy
すべてを表示

Spyre Therapeutics Inc (SYRE) 最新ニュース

pulisher
05:01 AM

Swiss National Bank Buys 19,000 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

05:01 AM
pulisher
Mar 27, 2025

Spyre Therapeutics Starts Dosing in Phase 1 Trial for IL-23 Antibody SPY003 - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Game-Changing IL-23 Antibody Enters Clinical Trials: Quarterly Dosing Could Transform Treatment - StockTitan

Mar 27, 2025
pulisher
Mar 26, 2025

Head to Head Contrast: Spyre Therapeutics (NASDAQ:SYRE) & Aptorum Group (NASDAQ:APM) - Defense World

Mar 26, 2025
pulisher
Mar 23, 2025

Charles Schwab Investment Management Inc. Has $8.84 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Bank of New York Mellon Corp Decreases Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Mar 22, 2025
pulisher
Mar 19, 2025

Spyre Therapeutics (NASDAQ:SYRE) Coverage Initiated by Analysts at Wolfe Research - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target -March 18, 2025 at 07:17 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 16, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Arizona State Retirement System - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

Victory Capital Management Inc. Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Mar 14, 2025
pulisher
Mar 08, 2025

Spyre Therapeutics Announces Grants of Inducement Awards - cnhinews.com

Mar 08, 2025
pulisher
Mar 07, 2025

Spyre Therapeutics Inc (SYRE) Announces Stock Option Grants to Non-Executive Employees - GuruFocus.com

Mar 07, 2025
pulisher
Mar 07, 2025

132,200 New Stock Options: Inside Spyre Therapeutics' Latest Employee Compensation Package - StockTitan

Mar 07, 2025
pulisher
Mar 06, 2025

Rhumbline Advisers Boosts Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Mar 06, 2025
pulisher
Mar 04, 2025

Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

Spyre Therapeutics Inc (SYRE) deserves closer scrutiny - US Post News

Mar 04, 2025
pulisher
Mar 04, 2025

Spyre Therapeutics: Targeting The Future Of IBD Treatment - Seeking Alpha

Mar 04, 2025
pulisher
Mar 02, 2025

Spyre Therapeutics (NASDAQ:SYRE) Trading 6.6% Higher After Strong Earnings - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Spyre Therapeutics (NASDAQ:SYRE) Posts Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Buy Rating for Spyre Therapeutics Driven by Promising Drug Development and Strong Financial Position - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Spyre Therapeutics: Q4 Earnings Snapshot - The Pioneer

Feb 28, 2025
pulisher
Feb 28, 2025

Decoding Spyre Therapeutics Inc (SYRE): A Strategic SWOT Insight - GuruFocus.com

Feb 28, 2025
pulisher
Feb 27, 2025

Spyre Therapeutics Reports Strong Progress and Financial Stability - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Spyre Therapeutics reports Q4 EPS (81c), consensus (94c) - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Spyre Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - PR Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Spyre Therapeutics (SYRE) Projected to Post Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Recent Insider Activity Could Benefit Spyre Therapeutics Inc (SYRE) - Knox Daily

Feb 26, 2025
pulisher
Feb 26, 2025

SYRE Stock Touches 52-Week Low at $20.24 Amid Market Challenges - Investing.com Australia

Feb 26, 2025
pulisher
Feb 25, 2025

Spyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year LowTime to Sell? - MarketBeat

Feb 25, 2025
pulisher
Feb 25, 2025

Spyre Therapeutics to Participate in Upcoming March Investor Conferences - PR Newswire

Feb 25, 2025
pulisher
Feb 25, 2025

IBD-Focused Spyre Therapeutics Sets Investor Conference Schedule for MarchWhat to Expect - StockTitan

Feb 25, 2025
pulisher
Feb 21, 2025

Spyre Therapeutics (NASDAQ:SYRE) Upgraded at The Goldman Sachs Group - Defense World

Feb 21, 2025
pulisher
Feb 20, 2025

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Feb 20, 2025
pulisher
Feb 19, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Can This Novel Dual-Action IBD Treatment Transform Patient Care? New Data Reveals Promising Results - StockTitan

Feb 19, 2025
pulisher
Feb 17, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Feb 17, 2025
pulisher
Feb 15, 2025

1,955 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World

Feb 15, 2025
pulisher
Feb 12, 2025

InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call - MSN

Feb 12, 2025
pulisher
Feb 10, 2025

Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect? - MSN

Feb 10, 2025
pulisher
Feb 10, 2025

InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call By Investing.com - Investing.com

Feb 10, 2025
pulisher
Feb 07, 2025

Spyre (SYRE) Unveils Strategic Talent Retention Plan: 35K Options with 10-Year Window - StockTitan

Feb 07, 2025
pulisher
Feb 06, 2025

China Universal Asset Management Co. Ltd. Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Feb 06, 2025
pulisher
Feb 05, 2025

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - cnhinews.com

Feb 05, 2025
pulisher
Feb 05, 2025

A company insider recently sold 6,700 shares of Spyre Therapeutics Inc [SYRE]. Should You also Consider to Sale? - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Financial Analysis: Spyre Therapeutics Inc (SYRE)’s Ratios Unveil Key Insights - The Dwinnex

Feb 05, 2025
pulisher
Feb 04, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - PR Newswire

Feb 04, 2025

Spyre Therapeutics Inc (SYRE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Spyre Therapeutics Inc (SYRE) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Albers Jeffrey W.
Director
Oct 25 '24
Sale
36.43
300
10,929
34,060
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):